We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84.7M
AUM Growth
-$13.5M
Cap. Flow
-$7.95M
Cap. Flow %
-9.38%
Top 10 Hldgs %
56.12%
Holding
79
New
15
Increased
14
Reduced
18
Closed
21
Avg Time Held
2.7 quarters
Top 10 Avg Time Held
2.9 quarters
Top 20 Avg Time Held
2.4 quarters

Top Buys

Rank Stock Value
1
IRMD icon
iRadimed
IRMD
+$3.43M
2
CYNO
Cynosure, Inc. Class A
CYNO
+$1.47M
3
LPSN icon
LivePerson
LPSN
+$1.37M
4
PCYO icon
Pure Cycle
PCYO
+$1.12M
5
SILC icon
Silicom
SILC
+$1.03M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$2.95M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$2.68M
3
BKNG icon
Booking.com
BKNG
+$1.68M
4
FLNA icon
Filana Therapeutics
FLNA
+$1.6M
5
CPRX icon
Catalyst Pharmaceutical
CPRX
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 44.42%
2 Technology 19.14%
3 Financials 8.41%
4 Communication Services 7.3%
5 Utilities 6.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZLTQ
1
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$8.7M 10.26%
384,418
-44,286
-10% -$877K
2013 Q2
5 quarters
BEAT icon
2
DELISTED
BioTelemetry, Inc.
BEAT
$7.56M 8.92%
1,126,974
-29,000
-3% -$203K
2013 Q2
5 quarters
MSTR icon
3
Strategy Inc
MSTR
$64.4B
$5.86M 6.91%
447,500
-62,500
-12% -$869K
2013 Q2
5 quarters
BFYT
4
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$5.61M 6.62%
519,870
-39,000
-7% -$487K
2014 Q1
2 quarters
PCYO icon
5
Pure Cycle
PCYO
$271M
$5.28M 6.23%
816,148
+170,148
+26% +$1.12M
2013 Q2
5 quarters
MEET
6
DELISTED
The Meet Group, Inc. Common Stock
MEET
$3.47M 4.1%
1,762,827
+100,000
+6% +$227K
2013 Q2
5 quarters
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.28M 3.88%
192,176
-203,100
-51% -$2.95M
2013 Q2
5 quarters
CDZI icon
8
Cadiz
CDZI
$288M
$2.68M 3.17%
258,279
+52,800
+26% +$542K
2013 Q3
4 quarters
IRMD icon
9
iRadimed
IRMD
$1.15B
$2.65M 3.13%
+378,771
New +$3.43M
2014 Q3
0 quarters
ARCT icon
10
Arcturus Therapeutics
ARCT
$342M
$2.47M 2.91%
22,832
-20,536
-47% -$2.68M
2013 Q3
4 quarters
RTK
11
DELISTED
Rentech, Inc.
RTK
$2.38M 2.81%
139,520
+37,922
+37% +$824K
2013 Q2
5 quarters
PKT
12
DELISTED
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
$2.31M 2.73%
240,906
-41,184
-15% -$410K
2013 Q2
5 quarters
FLNA icon
13
Filana Therapeutics
FLNA
$35.9M
$2.27M 2.68%
83,109
-52,800
-39% -$1.6M
2013 Q3
4 quarters
CSII
14
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.17M 2.56%
91,841
-1,100
-1% -$31.3K
2013 Q2
5 quarters
DRRX icon
15
DELISTED
DURECT Corp
DRRX
$1.77M 2.08%
120,211
-6,691
-5% -$104K
2014 Q2
1 quarter
SRL icon
16
Scully Royalty
SRL
$73.5M
$1.52M 1.79%
42,700
+14,680
+52% +$562K
2013 Q2
5 quarters
SHOR
17
DELISTED
ShoreTel, Inc.
SHOR
$1.49M 1.76%
224,560
+1,000
+0.4% +$6.47K
2014 Q1
2 quarters
LPSN icon
18
DELISTED
LivePerson
LPSN
$1.45M 1.71%
+7,700
New +$1.37M
2014 Q3
0 quarters
CYNO
19
DELISTED
Cynosure, Inc. Class A
CYNO
$1.41M 1.66%
+67,000
New +$1.47M
2014 Q3
0 quarters
SILC icon
20
Silicom
SILC
$315M
$1.4M 1.66%
48,100
+33,100
+221% +$1.03M
2014 Q2
1 quarter
ENT
21
DELISTED
Global Eagle Entertainment Inc.
ENT
$1.35M 1.6%
4,832
+1,160
+32% +$337K
2013 Q3
4 quarters
AXGN icon
22
Axogen
AXGN
$2.12B
$1.34M 1.59%
550,607
– –
2013 Q3
4 quarters
KFX
23
DELISTED
KOFAX LIMITED COM STK
KFX
$1.24M 1.46%
160,400
+25,500
+19% +$196K
2014 Q1
2 quarters
UI icon
24
Ubiquiti
UI
$37.5B
$1.19M 1.4%
31,713
-20,150
-39% -$856K
2013 Q2
5 quarters
AVAV icon
25
AeroVironment
AVAV
$6.46B
$1.15M 1.35%
38,100
+6,700
+21% +$213K
2013 Q3
4 quarters
1
2 3 4

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Sophrosyne Capital held 79 positions worth $84.7M, down 14% from $98.2M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sophrosyne Capital withdrew a net $7.95M in Q3 2014, closing 21 positions and reducing 18 holdings. Its most notable exit was Booking.com, an estimated $1.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Technology and Financials.

Against the trend, Sophrosyne Capital opened a new position in iRadimed worth $2.65M.

  • Sophrosyne Capital's largest Q3 2014 buy was iRadimed: 378,771 shares worth $2.65M.
  • Sophrosyne Capital added most to Pure Cycle in Q3 2014, an estimated $1.12M increase.
  • Sophrosyne Capital's biggest Q3 2014 reduction was BioDelivery Sciences International, Inc., cutting an estimated $2.95M.
  • Sophrosyne Capital fully exited Booking.com in Q3 2014, selling an estimated $1.68M.
  • Sophrosyne Capital's ten largest holdings make up 56% of its $84.7M portfolio in Q3 2014.
  • Sophrosyne Capital opened 15 new positions and closed 21 in Q3 2014.
  • Sophrosyne Capital's portfolio value fell 14% quarter-over-quarter to $84.7M.

Based on Sophrosyne Capital's 13F filing for Q3 2014, filed 14 Nov 2014.